This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Tandem Diabetes (TNDM) Global Pump Sales Aid, Price Issue Ails
by Zacks Equity Research
Tandem Diabetes (TNDM) is witnessing strong customer retention, driven by the impressive positive response from the Control-IQ technology.
Here's Why You Should Invest in AMN Healthcare (AMN) Stock Now
by Zacks Equity Research
AMN Healthcare (AMN) continues to benefit from its broad range of services.
Buy These 3 Low-Beta Stocks to Sail Through a Choppy Market
by Nilanjan Banerjee
It is imperative to build a portfolio of low-beta stocks to sail through a choppy market. United Therapeutics (UTHR), Sanderson (SAFM) and AMN Healthcare (AMN) are well poised to gain.
New Strong Buy Stocks for June 24th
by Zacks Equity Research
AMR, SBOW, AMN, BVH, and EGLE have been added to the Zacks Rank #1 (Strong Buy) List on June 24, 2022.
Where Do Pricy Tesla Shares Go from Here?
by John Blank
As important, does the S&P500 index follow along?
3 Reasons to Retain Nevro (NVRO) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Nevro (NVRO) owing to its strength in the global SCS market.
Change Healthcare (CHNG)-Luma Launch Patient Engagement Suite
by Zacks Equity Research
Change Healthcare's (CHNG) latest launch is expected to significantly improve patients' healthcare journey and create a more streamlined patient experience.
Here's Why You Should Retain Patterson Companies (PDCO) Stock
by Zacks Equity Research
Patterson Companies (PDCO) continues to benefit from its strength in the Animal Health business and robust product portfolio. However, stiff competition remains a woe.
BD (BDX) Integrates Innovative Solution to Boost Patient Care
by Zacks Equity Research
BD's (BDX) announcement of the implementation of BD HealthSight brings together timely monitoring to support the early detection of emerging healthcare infections, thereby improving patient care.
Here's Why You Should Retain Neogen (NEOG) Stock for Now
by Zacks Equity Research
Neogen's (NEOG) robust segmental performance and notable product launches instill investors' confidence.
UnitedHealth (UNH) Unit Unveils Solution to Provide Better Care
by Zacks Equity Research
UnitedHealth's (UNH) subsidiary Optum introduces a solution that can detect tests that are clinically backed, thereby minimizing unrequired tests and offering enhanced care to health plan members.
Tenet Healthcare (THC) Unit Ties Up to Boost Urology Services
by Zacks Equity Research
Tenet Healthcare's (THC) unit, USPI, signs a joint venture partnership with UUG to acquire ownership interests in the latter's 22 ambulatory surgery centers and concurrently assuring to develop these centers.
Here's Why You Should Hold on to Inogen (INGN) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Inogen (INGN) on its potential in the POC space and a strong product portfolio.
Here's Why Investors Should Retain Tandem Diabetes (TNDM) Now
by Zacks Equity Research
Investors are optimistic about Tandem Diabetes' (TNDM) strong pump shipments and ongoing product innovations.
Walgreens (WBA) to Offer Health Services to Ohio Medicaid Members
by Zacks Equity Research
Walgreens' (WBA) subsidiary teams up with Buckeye Health Plan to provide wellness services through Walgreens Health Corner locations in Ohio.
Veeva Systems (VEEV) Inks Deal to Serve Rare Disease Patients
by Zacks Equity Research
Adoption of Veeva Systems' (VEEV) cloud applications is likely to significantly boost its Veeva Development Cloud business.
National Vision (EYE) Gains on Volume Growth Amid Margin Woes
by Zacks Equity Research
National Vision (EYE) plans to continue executing its core growth initiatives and further investing in strengthening competitive advantages.
Here's How Much You'd Have If You Invested $1000 in AMN Healthcare Services a Decade Ago
by Zacks Equity Research
Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.
PerkinElmer (PKI) Unveils GC Platform to Simplify Lab Operations
by Zacks Equity Research
PerkinElmer's (PKI) newly introduced next-generation, automated GC platform can help simplify lab operations and offer excellent precision for high throughput environments.
Here's Why You Should Retain Inari Medical (NARI) Stock Now
by Zacks Equity Research
Inari Medical (NARI) continues to benefit from its commitment toward understanding the venous system. However, dependency on the wide adoption of products is a woe.
Here's Why You Should Retain National Vision (EYE) For Now
by Zacks Equity Research
Investors are optimistic about National Vision's (EYE) better-than-expected earnings and new store growth.
Here's Why Investors Should Retain LabCorp (LH) Stock for Now
by Zacks Equity Research
Investors are optimistic about LabCorp's (LH) robust Drug Development business performance and several pandemic-related developments.
Encompass Health (EHC) Opens EHR-Backed Hospital in Florida
by Zacks Equity Research
Encompass Health (EHC) takes its U.S. inpatient rehabilitation hospital count to 150 with the opening of a hospital in Florida integrated with the sound EHR system of Oracle Cerner.
Charles River (CRL) Prospers Internationally Amid FX Headwind
by Zacks Equity Research
Charles River (CRL) broadens the scope of the products and services across the drug discovery and early-stage development continuum through focused acquisitions.
Here's Why You Should Retain LHC Group (LHCG) Stock Now
by Zacks Equity Research
LHC Group (LHCG) continues to benefit from strategic deals and a broad array of services.